决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Fucoidan-Copper Nanoparticles to Potentiate Cancer Cell Cuproptosis and Tumor Immune Microenvironment Enhancement.
铜死亡是一种新近被阐明的调节性细胞死亡形式,由铜与三羧酸循环中脂酰化成分结合而引发,为癌症治疗提供了一个有前景的靶点。
铜死亡是一种新近被阐明的调节性细胞死亡形式,由铜与三羧酸循环中脂酰化组分结合而引发,为癌症治疗提供了一个有前景的靶点。在此,我们报道了岩藻多糖-铜纳米颗粒(Fu-Cu)的开发,该纳米颗粒利用这一机制选择性诱导HuH-7肝癌细胞产生细胞毒性。Fu-Cu以岩藻多糖——一种具有固有抗癌特性的硫酸化多糖——作为铜离子的天然纳米载体合成而成。表征结果证实铜成功掺入并形成了稳定的纳米颗粒。在HuH-7细胞中敲除铁氧还蛋白1可减轻Fu-Cu的细胞毒性作用,凸显了其在铜诱导细胞死亡中的关键作用。此外,我们在秀丽隐杆线虫中研究了Fu-Cu的毒性及机制效应。使用BALB/c裸鼠皮下肿瘤模型进行的体内研究表明,Fu-Cu有效抑制了肿瘤生长。值得注意的是,Fu-Cu治疗与肿瘤微环境中固有免疫细胞浸润增强相关,包括NK细胞和巨噬细胞募集增加,以及外周CD19 + B细胞频率升高。这些发现凸显了Fu-Cu作为一种新型肝细胞癌治疗策略的潜力,其同时利用铜死亡诱导和肿瘤免疫微环境增强来抑制肿瘤进展。
Cuproptosis, a newly characterized form of regulated cell death initiated by copper binding to lipoylated components of the tricarboxylic acid cycle, presents a promising target for cancer therapy. Here, we reported the development of fucoidan-copper nanoparticles (Fu-Cu) that exploit this mechanism to selectively induce cytotoxicity in HuH-7 liver cancer cells. Fu-Cu was synthesized using fucoidan, a sulfated polysaccharide with inherent anticancer properties, as a natural nanocarrier for copper ions. Characterization confirmed successful copper incorporation and the formation of stable nanoparticles. Knockout of ferredoxin 1 in HuH-7 cells mitigated the cytotoxic effects of Fu-Cu, underscoring its critical role in copper-induced cell death. Furthermore, we investigated the toxicity and mechanistic effects of Fu-Cu in Caenorhabditis elegans . In vivo studies using a subcutaneous tumor model in BALB/c nude mice demonstrated that Fu-Cu effectively inhibited tumor growth. Notably, Fu-Cu treatment was associated with enhanced innate immune cell infiltration in the tumor microenvironment, including increased NK-cell and macrophage recruitment, along with elevated peripheral CD19 + B-cell frequencies. These findings highlight Fu-Cu as a novel therapeutic strategy for hepatocellular carcinoma, leveraging both cuproptosis induction and tumor immune microenvironment enhancement to suppress tumor progression.
MEMBER ACCOUNT
登录成功会直接打开下一页。